Alembic Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2026, recommended Final Dividend of Rs. 12 per equity share.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹785.00

prior close

₹784.25

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-0.2% vs market

Pharmaceuticals peers, median of 160sector-0.1%-0.4% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.2

15m

+0.1

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.4-0.2-0.1-0.4

Next day

-7.5-1.7-5.8-0.9-6.7

-4.1-1.3-2.8-0.2-3.9

-4.5-0.7-3.8+0.3-4.8

-4.6+0.4-5.0+1.1-5.7

-3.6+0.5-4.1+0.2-3.8

-3.3+2.8-6.1+1.0-4.3

15d

-4.9+1.2-6.1-0.2-4.7

-5.9+5.3-11.2+1.7-7.6

+8.6+9.9-1.3+7.7+0.9

+4.9+13.1-8.2+8.1-3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals reported FY2026 standalone revenue of Rs. 6,651 crore, up 10.3% YoY from Rs. 6,033 crore. Consolidated revenue was Rs. 7,345 crore (up 10.1% YoY). Standalone PAT grew 27.3% to Rs. 640 crore versus Rs. 503 crore last year. EBITDA margin expanded from 15.74% to 16.82% while net profit margin improved from 8.34% to 9.63%. The Board recommended a final dividend of Rs. 12 per share (600%), up from Rs. 11 (550%) last year. Exceptional items included Rs. 48.64 crore for new Labour Code provisions and Rs. 18.35 crore write-down on Sikkim facility assets held for sale, partially offset by Rs. 100.27 crore deferred tax asset recognition. Auditors issued an unmodified opinion.

Likely market impact

Strong earnings with PAT growth exceeding 25% and margin expansion signals operational efficiency. Dividend increase reflects healthy cash generation. The Sikkim facility write-down is non-recurring.